Effect of Covid-19 Epidemic on Primary PCI in Patients With STEMI

NCT ID: NCT04427735

Last Updated: 2020-06-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-24

Study Completion Date

2021-07-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The epidemic of covid-19 has spread all over the world and has a great impact on people's health and life. It is necessary to study the treatment of STEMI patients in the real world under the influence of the epidemic,which provide effective suggestions and strategies for emergency and severe treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The epidemic of covid-19 has spread all over the world and has a great impact on people's health and life. The patients' prognosis is poor because the epidemic situation runs on medical resources, delays the diagnosis and treatment of other diseases such as cardiovascular diseases, and the patients' willingness to see a doctor is reduced. In particular, the delay in the treatment of STEMI, which needs PCI treatment, will cause more damage to the patients. It is necessary to study the treatment of STEMI patients in the real world under the influence of the epidemic. In this study, STEMI patients who experienced emergency PCI treatment after the covid-19 outbreak in 2020 were included, and compared with the data of the same period in 2019,we will analyze the pre hospital treatment time, vascular opening time,and the major cardiovascular adverse events, which provide effective suggestions and strategies for emergency and severe treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

STEMI

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

before COVID-19

Patients with myocardial infarction from January 24, 2019 to June 24, 2019

No interventions assigned to this group

after COVID-19

Patients with myocardial infarction from January 24, 2020 to June 24, 2020

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Continuous inclusion of patients with definite diagnosis of acute ST segment elevation myocardial infarction and emergency PCI intervention.

Exclusion Criteria

* Febrile patients, patients with severe infection,
* ST segment elevation myocardial infarction during hospitalization,
* Patients who could not cooperate with each other.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beijing Friendship Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hongwei Li, MD

professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hongwei Li

Role: STUDY_CHAIR

Beijing Friendship Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Beijing Friendship Hospital, Capital Medical University

Beijing, , China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hongwei Li, doctor

Role: CONTACT

0086 10 63139780

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hongwei Li

Role: primary

0086 10 63139780

Xuhe Gong

Role: backup

0086 10 63139780

References

Explore related publications, articles, or registry entries linked to this study.

Gong X, Zhou L, Dong T, Ding X, Zhao H, Chen H, Li H. Impact of COVID-19 pandemic on STEMI undergoing primary PCI treatment in Beijing, China. Am J Emerg Med. 2022 Mar;53:68-72. doi: 10.1016/j.ajem.2021.11.034. Epub 2021 Nov 24.

Reference Type DERIVED
PMID: 34999563 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BFH-COVID-19 and Primary PCI

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

China STEMI-PCI Program
NCT01716884 UNKNOWN